Fed. Circ. Sides With GSK, Others In Argatroban IP Row

Law360, New York (August 2, 2011, 4:30 PM EDT) -- The Federal Circuit upheld a win Tuesday for GlaxoSmithKline PLC, Mitsubishi Chemical Corp. and Encysive Pharmaceuticals Inc. in a patent battle with Barr Laboratories Inc. over anti-coagulant drug Argatroban, affirming a decision that Barr's invalidity claims didn't hold water.

A three-judge panel denied defendant-appellant Barr's challenge to a lower court's judgment that the Mitsubishi patent-in-suit was valid.

Mitsubishi and the other plaintiffs slapped Barr with the suit after the company sought approval for a generic version of injectable Argatroban, and Barr argued that the four patent...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.